Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
Simulations Plus (Nasdaq: SLP) has announced a strategic restructuring of its business units and leadership to support future growth following recent acquisitions. The company is forming two new business units: Adaptive Learning & Insights and Medical Communications, while transitioning Regulatory Strategies into a Center of Excellence. This reorganization aims to enhance customer engagement, accelerate cross-selling opportunities, and maximize growth potential.
Key leadership changes include:
- Steven Chang promoted to President, Quantitative Systems Pharmacology
- Jenna Rouse promoted to President of Adaptive Learning & Insights
- Murry Alper promoted to President of Medical Communications
- Sandra Suarez-Sharp transitioning to President, Regulatory Strategies Center of Excellence
Simulations Plus (Nasdaq: SLP) ha annunciato una ristrutturazione strategica delle sue unità aziendali e della leadership per supportare la crescita futura a seguito di recenti acquisizioni. L'azienda sta formando due nuove unità aziendali: Adaptive Learning & Insights e Medical Communications, mentre trasforma Regulatory Strategies in un Centro di Eccellenza. Questa riorganizzazione mira a migliorare il coinvolgimento dei clienti, accelerare le opportunità di cross-selling e massimizzare il potenziale di crescita.
Le principali modifiche alla leadership includono:
- Steven Chang promosso a Presidente, Quantitative Systems Pharmacology
- Jenna Rouse promossa a Presidente di Adaptive Learning & Insights
- Murry Alper promosso a Presidente di Medical Communications
- Sandra Suarez-Sharp in transizione a Presidente, Regulatory Strategies Center of Excellence
Simulations Plus (Nasdaq: SLP) ha anunciado una reestructuración estratégica de sus unidades de negocio y liderazgo para apoyar el crecimiento futuro tras las recientes adquisiciones. La compañía está formando dos nuevas unidades de negocio: Adaptive Learning & Insights y Medical Communications, mientras que la actividad de Regulatory Strategies se transformará en un Centro de Excelencia. Esta reorganización tiene como objetivo mejorar el compromiso con los clientes, acelerar las oportunidades de venta cruzada y maximizar el potencial de crecimiento.
Los principales cambios en el liderazgo incluyen:
- Steven Chang nombrado Presidente de Quantitative Systems Pharmacology
- Jenna Rouse nombrada Presidenta de Adaptive Learning & Insights
- Murry Alper nombrado Presidente de Medical Communications
- Sandra Suarez-Sharp en transición a Presidenta del Centro de Excelencia de Regulatory Strategies
Simulations Plus (Nasdaq: SLP)는 최근 인수 후 향후 성장을 지원하기 위해 사업 부문과 리더십의 전략적 구조 조정을 발표했습니다. 이 회사는 Adaptive Learning & Insights와 Medical Communications라는 두 개의 새로운 사업 부문을 구성하며, Regulatory Strategies를 우수 센터로 전환합니다. 이 조직 개편은 고객 참여를 강화하고, 교차 판매 기회를 가속화하며, 성장 잠재력을 극대화하는 것을 목표로 합니다.
주요 리더십 변경 사항은 다음과 같습니다:
- Steven Chang가 Quantitative Systems Pharmacology의 사장으로 승진했습니다.
- Jenna Rouse가 Adaptive Learning & Insights의 사장으로 승진했습니다.
- Murry Alper이 Medical Communications의 사장으로 승진했습니다.
- Sandra Suarez-Sharp이 Regulatory Strategies 우수 센터의 사장으로 전환합니다.
Simulations Plus (Nasdaq: SLP) a annoncé une restructuration stratégique de ses unités opérationnelles et de son leadership pour soutenir la croissance future suite à des acquisitions récentes. L'entreprise forme deux nouvelles unités : Adaptive Learning & Insights et Medical Communications, tout en transformant Regulatory Strategies en un Centre d'Excellence. Cette réorganisation vise à améliorer l'engagement client, à accélérer les opportunités de vente croisée et à maximiser le potentiel de croissance.
Les principaux changements dans la direction comprennent :
- Steven Chang nommé Président de Quantitative Systems Pharmacology
- Jenna Rouse nommée Présidente d'Adaptive Learning & Insights
- Murry Alper nommé Président de Medical Communications
- Sandra Suarez-Sharp en transition vers Présidente du Centre d'Excellence en Regulatory Strategies
Simulations Plus (Nasdaq: SLP) hat eine strategische Umstrukturierung seiner Geschäftsbereiche und Führungskräfte angekündigt, um zukünftiges Wachstum nach den jüngsten Übernahmen zu unterstützen. Das Unternehmen gründet zwei neue Geschäftsbereiche: Adaptive Learning & Insights und Medical Communications, während Regulatory Strategies in ein Kompetenzzentrum umgewandelt wird. Diese Neuorganisation zielt darauf ab, die Kundenbindung zu verbessern, Cross-Selling-Möglichkeiten zu beschleunigen und das Wachstumspotenzial zu maximieren.
Wichtige Änderungen in der Führung umfassen:
- Steven Chang wurde zum Präsidenten von Quantitative Systems Pharmacology ernannt.
- Jenna Rouse wurde zur Präsidentin von Adaptive Learning & Insights ernannt.
- Murry Alper wurde zum Präsidenten von Medical Communications ernannt.
- Sandra Suarez-Sharp wechselt zur Präsidentin des Regulatory Strategies Kompetenzzentrums.
- Strategic restructuring to support future growth and maximize opportunities
- Formation of new business units to enhance customer engagement
- Transition of Regulatory Strategies into a Center of Excellence to accelerate cross-selling
- Doubling of total addressable market through recent acquisitions
- Development of a one-of-a-kind platform spanning the drug development continuum
- Promotion of experienced leaders to key positions
- Departure of two key executives: Brett Howell and Michael Raymer
Announces leadership appointments for newly structured business units
“Over the past year, we made two key acquisitions, including the largest in our corporate history,” said Shawn O’Connor, Chief Executive Officer. “As a result, we have doubled our total addressable market, developed a one-of-a-kind platform, and significantly bolstered our talent pool. While integrating Pro-ficiency into our platform, we identified synergies and opportunities to reorganize our business units and leadership structure to better serve our clients and maximize our growth opportunities. Above all, our expanded team of top industry talent is united by the shared mission to create value for our customers by accelerating the development and delivery of drugs to patients.
“In bringing Pro-ficiency on board, we focused on effective optimization of people and resources. As a result, we are forming two new and distinct business units — Adaptive Learning & Insights and Medical Communications — to enhance our customer engagement with both current and potential clients. We are also transitioning the Regulatory Strategies business unit into a new Regulatory Strategies Center of Excellence. This change is expected to enhance visibility within the sales organization and accelerate cross-selling opportunities driven by the increasing demand for biosimulation solutions.
“Our suite of end-to-end and innovative offerings now spans the drug development continuum which we believe puts Simulations Plus in a unique competitive position to scale the business to drive growth and profitability. Looking forward, we are excited about the potential we see to create long-term value for all our stakeholders.”
Simulations Plus announced the following leadership promotions and transitions:
Steven Chang will be promoted to President, Quantitative Systems Pharmacology. Mr. Chang joined Simulations Plus in June 2023 with the acquisition of Immunetrics and served as its President and Chief Executive Officer since 2002. He is a successful technology entrepreneur with more than three decades of experience in identifying emerging market needs and combining state-of-the-art technologies and resources to meet those needs.
Jenna Rouse will be promoted to President of the newly formed Adaptive Learning & Insights business unit. Ms. Rouse joined Simulations Plus with the acquisition of Pro-ficiency where, as Chief Markets Officer, Clinical, she spent five years driving the growth and engagement with the organization’s simulation-enabled training solutions for clinical trial optimization, competency development, and continuing medical education. Prior to joining Pro-ficiency, she spent 25 years in workforce development in regulated industries, with over 15 years dedicated to professional development and adult learning in clinical trials.
Murry Alper will be promoted to President of the newly formed Medical Communications business unit. Mr. Alper joined Simulations Plus with the acquisition of Pro-ficiency. Mr. Alper brings almost 30 years of experience in the life sciences industry, with experience at both major developers, as well as on the agency side. Mr. Alper founded Caravel Group in 2006 after a decade in marketing and sales roles at Bristol-Myers Squibb and Genentech. He has co-founded multiple medical communications agencies and was Managing Partner of Compass Group Partners upon its purchase by Pro-ficiency in June of 2023.
Sandra Suarez-Sharp, Ph.D., will transition to President, Regulatory Strategies Center of Excellence. Dr. Suarez-Sharp joined Simulations Plus in 2020 and has been instrumental in facilitating the Company’s regulatory support to clients. Prior to joining Simulations Plus, Dr. Suarez-Sharp had a long and successful career at the Food and Drug Administration, including roles in biopharmaceutics, bioequivalence, and clinical pharmacology. In her new role, she is responsible for expanding the Regulatory Strategies Center of Excellence to accelerate cross-selling opportunities driven by the rapidly growing demand for biosimulation solutions.
The Company also announced the following departures:
Brett Howell, Ph.D., President, Quantitative Systems Pharmacology and Michael Raymer, President, Clinical Simulations & Medical Communications will be leaving Simulations Plus after assisting with the transition process.
O’Connor concluded: “We are grateful for Dr. Howell’s leadership and contributions to the Company. Under his guidance, our QSP business has achieved remarkable milestones since the acquisition of DILIsym in 2017. In addition, Mr. Raymer played an instrumental role in the acquisition and initial integration of Pro-ficiency. We wish both of them all the best in their future endeavors.”
About Simulations Plus
With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the Biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to successfully integrate the Pro-ficiency business with our own, as well as expenses we may incur in connection therewith, the efficiency and effectiveness of our internal business restructuring and leadership changes, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240823193956/en/
Investor Relations Contacts:
Lisa Fortuna
Financial Profiles
310-622-8251
slp@finprofiles.com
Renee Bouche
Simulations Plus Investor Relations
661-723-7723
renee.bouche@simulations-plus.com
Source: Simulations Plus, Inc.
FAQ
When will Simulations Plus (SLP) implement its new business unit structure?
What are the new business units created by Simulations Plus (SLP)?
Who has been promoted to President of Quantitative Systems Pharmacology at Simulations Plus (SLP)?
How has Simulations Plus (SLP) expanded its market through recent acquisitions?
What is the goal of Simulations Plus (SLP)'s business restructuring?
